Led by researchers at RCSI (Royal College of Surgeons in Ireland), a team of researchers has developed a new treatment for tuberculosis (TB). This work could offer a practical treatment that has the potential to be scaled-up and mass-produced for clinical testing.
The treatment, which patients will take using an inhaler, works by reducing the bacteria in the lungs that causes tuberculosis while also helping the patient’s immune system fight the disease.
There is only one vaccine for tuberculosis, developed in 1921. It is unreliable in preventing the most common form of TB, and is not suitable in all patient groups. The vaccine works best against specific forms of TB and is usually given to infants in at-risk populations.
Tuberculosis is one of the top 10 causes of death worldwide. The World Health Organization (WHO) data show that 10 million people fell ill with TB and 1.6 million died from the disease in 2017. WHO estimates that there were 558,000 new cases with resistance to the most effective first-line antibiotic. Of those resistant to the drug, 82% were resistant to multiple antibiotics.
Funded by the Health Research Board (HRB) and the Royal City of Dublin Hospital Trust, the research is published in the European Journal of Pharmaceutics & Biopharmaceutics.
The work, led by Dr Gemma O’Connor and Prof Sally-Ann Cryan in RCSI, was carried out in collaboration with research teams in St James Hospital, Trinity College Dublin and Imperial College London. Prof Joseph Keane and Dr Mary O’Sullivan led the team at St James Hospital and Trinity College Dublin with Dr Brian Robertson and Dr Nitya Krishnan leading the team at Imperial College London.
Multidrug-resistant TB (MDR-TB) is seen as both a public health crisis and a health security threat. Ending the TB epidemic by 2030 is listed among the health targets of the United Nations Sustainable Development Goals.
The pathogen that causes tuberculosis spreads by people breathing infected droplets into their lungs, where the disease can remain dormant or spread further. The research makes use of a derivative of Vitamin A called all trans retinoic acid, atRA, which previous studies have shown is an effective treatment for tuberculosis.
“Many cases of TB are now becoming resistant to existing antibiotics. This new treatment could be used alongside antibiotics to treat drug-resistant TB and also possibly reduce the rate of antibiotic resistance resulting from conventional antibiotic treatments,” said Prof Cryan, Associate Professor of Pharmaceutics in RCSI School of Pharmacy and the study’s senior author.
Using a spray-drying process, the researchers packaged atRA within safe-for-consumption particles that are small enough to use in an inhaler. These particles efficiently delivered the treatment and significantly reduced tuberculosis-causing bacteria and associated lung damage, which supports their potential for clinical testing.
“Unfortunately, tuberculosis remains a significant problem for world health. We urgently need innovative treatments like this one if we are to achieve the UN 2030 health targets,” said Prof Keane, Professor at Trinity College Dublin School of Medicine and Consultant Respiratory Physician in St James’s Hospital.
The Latest on: Tuberculosis
via Google News
The Latest on: Tuberculosis
- How NZ should respond to new Covid variationson January 12, 2021 at 8:30 am
University of Otago's Philip Hill and Brian Cox look at how findings about new Covid variations should influence our approach in NZ.
- Nigeria: HIV, Tuberculosis Care Neglected Due to Covid-19 - Health Ministeron January 12, 2021 at 6:18 am
The Minister of state for health, Senator Olorunnimbe Mamora has revealed that the care and attention given to HIV, tuberculosis and other ailments have been neglected due to the impact of COVID-19 ...
- Eight tuberculosis cases in Noida, third round of screening soonon January 8, 2021 at 6:42 pm
Eight cases of tuberculosis have been detected in Gautam Budh Nagar during the first and second phase of active case finding (ACF) drive that was held ...
- Tuberculosis Vaccine Treatment Market 2020 Driving Factors, Industry Growth, Key Vendors and Forecasts to 2025on January 8, 2021 at 9:07 am
Selbyville, Delaware, The next five years the Tuberculosis Vaccine Treatment market will register a 3.0% CAGR in terms of revenue, the global market size will reach $ 77 million by 2025, from $ 69 ...
- Global Tuberculosis Testing Market Report 2020: Market Analysis and Forecast, 2017-2025 by Test Type, End User & Regionon January 8, 2021 at 8:30 am
Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2025" report has been added to ResearchAndMarkets.com's offering. This report on the global Tuberculosis Testing Market studies ...
- Global Tuberculosis Testing Market Report 2020: Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2025 - ResearchAndMarkets.comon January 7, 2021 at 2:57 am
Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2025” report has been added to ResearchAndMarkets.com’s offering. This report on the global Tuberculosis Testing Market studies ...
- Global Tuberculosis Testing Market Report 2020: What Will be the Y-o-Y Growth of the Market Between 2019 and 2027on January 6, 2021 at 7:11 am
Dublin, Jan. 06, 2021 (GLOBE NEWSWIRE) -- The "Tuberculosis Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2025" report has been added to ...
- EU gives Libya USD4.04m for tuberculosis controlon January 5, 2021 at 6:52 pm
The International Organization for Migration (IOM) and the World Health Organization (WHO) affirmed on Sunday, January 53, that the EU backing of over 3.3 million Euros (USD4.04 million) for an ...
- Tuberculosis Testing Market by Manufacturers, Regions, Type and Application Forecast to 2025on January 5, 2021 at 4:54 am
The global Tuberculosis Testing market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.8%% in the forecast period of 2020 to 2025 and will expected to ...
- EU supports Libya 3.3 mln euros for tuberculosis managementon January 4, 2021 at 12:24 pm
(Xinhua) -- The International Organization for Migration (IOM) and the World Health Organization (WHO) confirmed on Sunday the EU support of over 3.3 million Euros (4.04 million U.S. dollars) for an ...
via Bing News